期刊
THROMBOSIS AND HAEMOSTASIS
卷 109, 期 1, 页码 24-33出版社
GEORG THIEME VERLAG KG
DOI: 10.1160/TH12-05-0302
关键词
F9; haemophilia B; mutation; FIX inhibitors; CSGE
资金
- Rene Baron Foundation
- Alberto J. Roemmers Foundation
- Florencio Fiorini Foundation
- Novo Nordisk Argentina
- Academia Nacional de Medicina de Buenos Aires
- National Research Council (CONICET)
- National Agency for Science and Technology Promotion (ANPCyT)
- Word Federation of Hemophilia
In haemophilia B (HB) (factor IX [FIX] deficiency), F9 genotype largely determines clinical phenotype. Aimed to characterise Argentinian families with HB, this study presents F9 genotype frequencies and their specific FIX inhibitor risk and 10 novel F9 mutations. Ninety-one DNA samples from HB patients and relatives were subjected to a new; scheme: a primary screen for large deletions, a secondary screen for point mutations using conformation sensitive gel electrophoresis, DNA-sequencing and bioinformatic analysis. Our unbiased HB population (N=52) (77% with severe, 11.5% moderate and 11.5% mild HB) showed 32 missense (61.5%), including three novel mutations predicting specific structural/functional defects in silico, seven nonsense (13.5%) (one novel), five large deletions, four splice including three novel mutations affecting predicted splicing scores, three indels (two novel) and one Leiden mutation. Our comprehensive HB population included five patients with long-lasting FIX inhibitors: three nonsense (p.E35(star) (novel), p.R75(star), p.W240(star)) and two entire-F9 deletions. Another patient with an indel (p.A26Rfsp(star)14) developed transient inhibitors. A case-control analysis, based on our global prevalence of 3.05% for developing inhibitors in HB revealed that missense mutations were associated with a low risk odds ratio (OR) of 0.05 and a prevalence of 0.39%, whereas nonsense and entire-F9 deletions had significantly higher risks (OR 11.0 and 32.7) and prevalence (14.3%, and 44.5%, respectively). Our cost-effective practical approach enabled identification of the causative mutation in all 55 Argentine families with HB, analysis of the molecular pathology of novel F9 defects and determination of mutation-associated FIX inhibitor risks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据